HIRA

코로나19 대응 의료기관에 대한 재정적 지원방식 사례 연구

  • 111
  • 111
Metadata Downloads
Type
Research report
Author(s)
이정은김주영한주희
Issued Date
2023-10
Keyword
코로나19의료기관 재정지원의료기관 손실보상코로나19 환자 병상확보Financial support for medical institutuionsCompensation for losses for medical institutionsSecuring of beds for COVID-19 patients
Abstract
Korea initially adopted a policy of universal hospitalization for all confirmed cases, regardless of symptoms, to prevent the spread of COVID-19 in the absence of vaccines and treatments. This led to a shortage of beds to accommodate COVID-19 patients. The government compensated medical institutions that provided beds to address the shortage of beds. This study reviewed the compensation methods and levels of Korea and foreign countries during the COVID-19 period to build a sustainable financial support system for future infectious disease situations.
The study results are as follows.
(Korea) The mortality rate of COVID-19 patients is about 0.1%, and the total expenditure due to COVID-19 is about 22.7 trillion won.
(Japan) The mortality rate of COVID-19 patients is about 0.2%, and the total expenditure due to COVID-19 is about 106 trillion won.
(Germany) The mortality rate of COVID-19 patients is about 0.4%, and the total expenditure due to COVID-19 is about 72 trillion won.
(Taiwan) The mortality rate of COVID-19 patients is about 0.4%, and the total expenditure due to COVID-19 is about 7.8 trillion won.
Many experts around the world predict that a large-scale infectious disease like COVID-19 will occur in the near future. This study is expected to be used as evidence for building a sustainable financial support system in the event of a future infectious disease situation.
Publisher
건강보험심사평가원
URI
https://repository.hira.or.kr/handle/2019.oak/3214
Alternative Title
A study on financial support methods for medical institutions in response to COVID-19: Focusing on the cases of foreign countries
Table Of Contents
제1장 서론 ··············································································· 1
1. 연구 배경 ······························································································ 1
2. 연구 목적 ······························································································ 2
3. 연구 내용 및 방법 ·················································································· 2

제2장 국내 코로나19 재정지원 현황 ··············································································· 3
1. 한국의 코로나19 상황 및 대응 ································································ 5
가. 코로나19 상황 ··························································································· 5
나. 코로나19 대응현황 ····················································································· 9
2. 코로나19 관련 재정지원 대상 ································································ 10
3. 재정지원 방식 ······················································································ 12
가. 비용 지원 ································································································ 12
나. 인력 지원 ································································································ 13
다. 치료비 지원 ····························································································· 13
4. 재정지원 근거 ······················································································ 14
가. 관련 법령 ································································································ 14
나. 재정지원 비용 산출방식 ············································································· 15
5. 지원금 ································································································· 17
가. 국고 ········································································································ 17
나. 건강보험 ·································································································· 17
6. 소결 ···································································································· 20

제3장 국외 코로나19 재정지원 현황 ··············································································· 21
1. 일본 ···································································································· 23
가. 보건의료 제도 ·························································································· 23
나. 일본의 코로나19 상황 및 대응 ·································································· 27
다. 일본의 코로나19 관련 재정지원 정책 ························································· 31
라. 소결 ········································································································ 38
2. 독일 ···································································································· 40
가. 보건의료 제도 ·························································································· 40
나. 독일의 코로나19 상황 및 대응 ·································································· 44
다. 독일의 코로나19 관련 재정지원 정책 ························································· 50
라. 소결 ········································································································ 53
3. 대만 ···································································································· 55
가. 보건의료 제도 ·························································································· 55
나. 대만의 코로나19 상황 및 대응 ·································································· 59
다. 대만의 코로나19 관련 재정지원 정책 ························································· 63
라. 소결 ········································································································ 71

제4장 재정지원 효과 ··············································································· 73
1. 코로나 병상 확보 ················································································· 75
가. 한국 ········································································································ 75
나. 외국 ········································································································ 76
2. 의료이용 결과 ······················································································ 77

제5장 결론 ··············································································· 79

◾ 참고 문헌 ······················································································· 85
◾ 부록 ······························································································· 93
◾ ABSTRACT ··················································································· 99
Publisher
건강보험심사평가원
Location
KOR
Citation
이정은. (2023-10). 코로나19 대응 의료기관에 대한 재정적 지원방식 사례 연구.
Appears in Collections:
HIRA 연구 > 1. 자체연구
공개 및 라이선스
  • 공개 구분공개
파일 목록

열람하신 정보에 대해 만족하십니까?

기타의견

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.